Journal of the American Society of Hypertension
Volume 4, Issue 4 , Pages 163-173, July 2010

Antihypertensive drug development: current challenges and future opportunities

  • Peter U. Feig, MD

      Affiliations

    • Cardiovascular Clinical Research, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Rahway, New Jersey
    • Corresponding Author InformationCorresponding author: Peter U. Feig, MD, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., 126 E. Lincoln Ave, RY34 A200, P.O. Box 2000, Rahway, NJ 07065-0900. Tel: 732-594-3229.
  • ,
  • Sophie Roy, PhD

      Affiliations

    • Cardiovascular Basic Research, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Rahway, New Jersey
  • ,
  • Robert J. Cody, MD

      Affiliations

    • Global Scientific Affairs, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Rahway, New Jersey

Received 26 March 2010; accepted 14 April 2010. published online 01 June 2010.

Abstract 

The growing rate of obesity and diabetes, and an aging population has led to increased demand for new antihypertensive compounds. This review highlights the challenges and opportunities associated with each phase of drug discovery and development of novel antihypertensive agents. Discovery and development starts with identification of a protein hypothesized to be linked to hypertension. Using the information gathered during this early stage, several potential candidates are often synthesized and moved on through preclinical evaluations, eventually leading to selection of one or more compounds for testing in humans. The compounds then enter preclinical safety studies in laboratory animal species and subsequently are tested in tiered clinical studies. As the compounds enter clinical testing, there is an exponential increase in the investment of resources to demonstrate that a new compound is a viable and worthy therapeutic agent for hypertension. The review provides some forecasting of issues that are likely to impact drug development of novel antihypertensives in the future.

Keywords: Hypertensive, drug development

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1933-1711(10)00088-4

doi:10.1016/j.jash.2010.04.003

Journal of the American Society of Hypertension
Volume 4, Issue 4 , Pages 163-173, July 2010